FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3021907264> ?p ?o ?g. }

• W3021907264 abstract "You have accessJournal of UrologyKidney Cancer: Advanced (including Drug Therapy) II (PD39)1 Apr 2020PD39-09 DOES AN ALTERNATIVE SUNITINIB DOSING SCHEDULE REALLY IMPROVE SURVIVAL OUTCOMES OVER A CONVENTIONAL DOSING SCHEDULE IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA? AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS Doo Yong Chung*, Beom-Yong Rho, Dong Hyuk Kang, Young Deuk Choi, and Kang Soo Cho Doo Yong Chung*Doo Yong Chung* More articles by this author , Beom-Yong RhoBeom-Yong Rho More articles by this author , Dong Hyuk KangDong Hyuk Kang More articles by this author , Young Deuk ChoiYoung Deuk Choi More articles by this author , and Kang Soo ChoKang Soo Cho More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000918.09AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Treatment-related adverse events (AEs) can obfuscate the maintenance of a conventional schedule of sunitinib in patients with metastatic renal cell carcinoma(mRCCa). Accordingly, alternative schedules seeking to improve the safety profile of sunitinib have been tested. Recently, two meta-analyses similarly described improved safety profiles favoring a 2-weeks-on and 1-week-off (2/1) schedule, but conflicting results for survival outcomes. Therefore, we conducted an updated systematic review and meta-analysis including all recently published studies and using complementary statistical methods. METHODS: Systematic literature searches were conducted in PubMed/Medline and Embase for all studies that examined alternative treatment of sunitinib for mRCCa. We performed this study according to the Preferred Reported Items for Systematic Reviews and Meta-analysis guidelines. Endpoints included progression-free survival, overall survival, and AEs of 15 types. Eleven articles were included in this meta-analysis. RESULTS: Using adjusted findings, we noted statistically better results in progression-free survival (hazard ratio, 0.58; 95% confidence interval, 0.39-0.84; P=0.005), but no difference in overall survival (hazard ratio, 0.66; 95% confidence interval, 0.42-1.04; P=0.08). Moreover, 2/1 schedule was beneficial for reducing the incidence of several AEs. Conclusively, our meta-analysis suggests that /1 schedule holds promise as an alternative means of reducing AEs and maintaining patient quality of life. CONCLUSIONS: Our meta-analysis suggests that alternative 2/1 sunitinib dosing schedule may have better PFS than conventional 4/2 sunitinib schedule. However, its level of evidence was very low, the interpretation of this result should be cautious. Moreover, the 2/1 schedule was beneficial for reducing the incidence of AEs. Accordingly, the 2/1 sunitinib dosing schedule holds promise as an alternative means of reducing AEs, maintaining patient QOL and prolonging treatment. Source of Funding: There was no funding provided in the current research. © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e812-e812 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Doo Yong Chung* More articles by this author Beom-Yong Rho More articles by this author Dong Hyuk Kang More articles by this author Young Deuk Choi More articles by this author Kang Soo Cho More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W3021907264 created "2020-05-13" @default.
• W3021907264 creator A5005420769 @default.
• W3021907264 creator A5049287840 @default.
• W3021907264 creator A5051318268 @default.
• W3021907264 creator A5077899911 @default.
• W3021907264 creator A5090913495 @default.
• W3021907264 date "2020-04-01" @default.
• W3021907264 modified "2023-10-06" @default.
• W3021907264 title "PD39-09 DOES AN ALTERNATIVE SUNITINIB DOSING SCHEDULE REALLY IMPROVE SURVIVAL OUTCOMES OVER A CONVENTIONAL DOSING SCHEDULE IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA? AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS" @default.
• W3021907264 doi "https://doi.org/10.1097/ju.0000000000000918.09" @default.
• W3021907264 hasPublicationYear "2020" @default.
• W3021907264 type Work @default.
• W3021907264 sameAs 3021907264 @default.
• W3021907264 citedByCount "0" @default.
• W3021907264 crossrefType "journal-article" @default.
• W3021907264 hasAuthorship W3021907264A5005420769 @default.
• W3021907264 hasAuthorship W3021907264A5049287840 @default.
• W3021907264 hasAuthorship W3021907264A5051318268 @default.
• W3021907264 hasAuthorship W3021907264A5077899911 @default.
• W3021907264 hasAuthorship W3021907264A5090913495 @default.
• W3021907264 hasBestOaLocation W30219072641 @default.
• W3021907264 hasConcept C126322002 @default.
• W3021907264 hasConcept C143998085 @default.
• W3021907264 hasConcept C17744445 @default.
• W3021907264 hasConcept C177713679 @default.
• W3021907264 hasConcept C189708586 @default.
• W3021907264 hasConcept C197934379 @default.
• W3021907264 hasConcept C199539241 @default.
• W3021907264 hasConcept C2777288759 @default.
• W3021907264 hasConcept C2777472916 @default.
• W3021907264 hasConcept C2779473830 @default.
• W3021907264 hasConcept C2779490328 @default.
• W3021907264 hasConcept C71924100 @default.
• W3021907264 hasConcept C95190672 @default.
• W3021907264 hasConceptScore W3021907264C126322002 @default.
• W3021907264 hasConceptScore W3021907264C143998085 @default.
• W3021907264 hasConceptScore W3021907264C17744445 @default.
• W3021907264 hasConceptScore W3021907264C177713679 @default.
• W3021907264 hasConceptScore W3021907264C189708586 @default.
• W3021907264 hasConceptScore W3021907264C197934379 @default.
• W3021907264 hasConceptScore W3021907264C199539241 @default.
• W3021907264 hasConceptScore W3021907264C2777288759 @default.
• W3021907264 hasConceptScore W3021907264C2777472916 @default.
• W3021907264 hasConceptScore W3021907264C2779473830 @default.
• W3021907264 hasConceptScore W3021907264C2779490328 @default.
• W3021907264 hasConceptScore W3021907264C71924100 @default.
• W3021907264 hasConceptScore W3021907264C95190672 @default.
• W3021907264 hasIssue "Supplement 4" @default.
• W3021907264 hasLocation W30219072641 @default.
• W3021907264 hasOpenAccess W3021907264 @default.
• W3021907264 hasPrimaryLocation W30219072641 @default.
• W3021907264 hasRelatedWork W1895933560 @default.
• W3021907264 hasRelatedWork W2056402925 @default.
• W3021907264 hasRelatedWork W2072245035 @default.
• W3021907264 hasRelatedWork W2171237277 @default.
• W3021907264 hasRelatedWork W2469034648 @default.
• W3021907264 hasRelatedWork W2544140097 @default.
• W3021907264 hasRelatedWork W2805430385 @default.
• W3021907264 hasRelatedWork W2971476881 @default.
• W3021907264 hasRelatedWork W3151554875 @default.
• W3021907264 hasRelatedWork W4205243027 @default.
• W3021907264 hasVolume "203" @default.
• W3021907264 isParatext "false" @default.
• W3021907264 isRetracted "false" @default.
• W3021907264 magId "3021907264" @default.
• W3021907264 workType "article" @default.